24 maj: NPinvestor.com A/S: Jan Svane Mathiesen tiltræder som adm. direkt..
24 maj: Storaktionærmeddelelse med SKAKO A/S' aktier
24-05-2018 12:20:59

Genmab Announces Topline Results in Phase III study of Arzerra® in Indolent Non-Hodgkin’s Lymphoma

Relateret indhold
Relateret debat
08:14 - 
Mht. investering.   Der er forskel på at lig..
07:52 - 
Min anke er .. og har været .. at Jan nu i 3 &ari..
17 jul - 
Fastholder kursmål på 1900 er vist mere korrekt

Company Announcement

  • Topline results from Phase III study in iNHL did not meet primary endpoint of improved progression-free survival

Copenhagen, Denmark; May 24, 2018 –

Genmab A/S (Nasdaq Copenhagen: GEN) announced today that topline results from the Phase III study of Arzerra® (ofatumumab) plus bendamustine did not meet the primary endpoint of improved progression-free survival (PFS) in patients with indolent B-cell non-Hodgkin's lymphoma (iNHL) who were unresponsive to rituximab or a rituximab-containing regimen, compared to those given bendamustine alone. The safety profile observed in this study was consistent with that observed in other trials of ofatumumab and no new safety signals were observed.

“We are disappointed that the ofatumumab treatment regimen did not meet the primary endpoint in this trial. The completion of this Phase III study, which began in 2010, would not have been possible without the generous participation of the patients and their families, and we are most grateful for this. The full data will be submitted for publication at a future medical conference and we hope that these will provide a better understanding of this result,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

The results from this Phase III study do not impact any other ongoing studies with ofatumumab.

About the study (COMPLEMENT A+B)

The study is an open-label, two-arm, randomized, Phase III study that included 346 patients with indolent B-cell non-Hodgkin's lymphoma who were unresponsive to rituximab or a rituximab-containing regimen. Patients in the study were randomized 1:1 to treatment with up to eight cycles of bendamustine given in combination with 12 doses of ofatumumab (1,000 mg) or up to eight cycles with bendamustine alone. The primary endpoint of the study was PFS.

Ofatumumab is not approved for the treatment of indolent non-Hodgkin’s Lymphoma.

About Ofatumumab (Arzerra®)

Ofatumumab is a human monoclonal antibody that is designed to target the CD20 molecule found on the surface of normal B lymphocytes and on B cell malignancies (including chronic lymphocytic leukemia and non-Hodgkin’s lymphomas).

In the United States, Arzerra is approved for use in combination with chlorambucil for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate, in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed CLL and for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL. In the European Union, Arzerra is approved for use in combination with chlorambucil or bendamustine for the treatment of patients with CLL who have not received prior therapy and who are not eligible for fludarabine-based therapy and in combination with fludarabine and cyclophosphamide for adult patients with relapsed CLL. In more than 60 countries worldwide, including the United States and EU member countries, Arzerra is also indicated as monotherapy for the treatment of patients with CLL who are refractory after prior treatment with fludarabine and alemtuzumab. On January 22, 2018, it was announced that Novartis intends to transition Arzerra for the treatment of CLL indications from commercial availability to limited availability via compassionate use programs in non-U.S. markets.

Please see full Prescribing Information, including Boxed WARNING for Arzerra (ofatumumab).

Arzerra is marketed under a collaboration agreement between Genmab and Novartis. A subcutaneous formulation of ofatumumab is also being investigated in two Phase III clinical studies in relapsing multiple sclerosis.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers, and solid tumors.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies.  The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

Contact:          

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications

T: +45 33 44 77 20; M: +45 25 12 62 60; E: rcg@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

Company Announcement no. 15

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment

Primary Logo

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
13 jul
GEN
Det vil være vild fedt,hvis de hoster op med 18 milliarder,det betyder nok et overskud i nærheden af..
9
14 jul
GEN
TheNote har råbt og skreget efter Jan over han ikke får “skrevet nogen aftaler” - men så snart der k..
5
17 jul
GEN
http://borsen.dk/nyheder/virksomheder/artikel/1/365823/salget_af_genmabs_guldaeg_overgaar_alle_forve..
3
12 jul
GEN
Kun tiden kan vise det. Kommer der et nyt vidundermiddel, vil patienter og investorer glæde sig.
3
17 jul
GEN
Der er bare shorterne der holder den nede,den skal nok komme op igen,gemmer mine og tror på 1500.- i..
2
12 jul
GEN
Lander vi Q2 med +500 mio usd inkl ROW tirsdag, så kan det alene give et sus opad... Gav 11% ved Q1...
2
12 jul
GEN
Ja hvad skal man sige til alle de kloge? Lad stilheden svare🤡📈📈📈📈📈
2
17 jul
GEN
Jeffrie sætter kursmål på 1900 !! Run run Genmab. Har naturligvis aktien.   GENMAB/JEFFERIES: DARZAL..
1
17 jul
GEN
511 - hvad sagde jeg
1
13 jul
GEN
The Note har sortsyn hvad angår Genmab alt er dårligt, selv store indtægter som i det her tilfælde.
1

Fondsbørsmeddelelser

#

EuroInvestor: I fokus
#

#

EuroInvestor: I fokus
#

#

EuroInvestor: I fokus
#

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Danske Bank skuffer i andet kvartal og skruer lidt ned for prognosen
2
Aktier/tendens: Danske Bank tager fokus op til forventet grøn åbning
3
Genmab/Jefferies: Darzalex øger tilliden til ledelsens forventninger
4
Aktier/åbning: Danske Bank skraber bunden i generelt negativt C25
5
Ericsson overraskede analytikerne

Relaterede aktiekurser

Genmab A/S 1.136,50 1,9% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Seneste nyheder


Copyright Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
18. juli 2018 14:56:02
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180712.1 - EUROWEB5 - 2018-07-18 14:56:02 - 2018-07-18 14:56:02 - 1 - Website: OKAY